Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tinnitus 1Ototoxicity 1Lung Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Deafness 1

Interventions

pembrolizumab 9Cetuximab 5Surveys and Questionnaires 4Cisplatin 4dostarlimab 2abemaciclib 2Standard of Care 2Docetaxel 2Carboplatin 2130-nm albumin-bound paclitaxel 2ulixertinib 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1tipifarnib 1ribociclib 1repotrectinib 1patritumab deruxtecan 1palbociclib 1olaparib 1nimotuzumab 1monalizumab 1ibrutinib 1fludarabine 1exemestane 1entrectinib 1ebselen 1durvalumab 1disitamab vedotin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × ebselen × 30 days × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡